Serum S100b: Biochemical marker of brain damage in newborns with hypoxic ischemic encephalopathy

Background. Hypoxic ischemic encephalopathy (HIE) is a major cause of neurological disabilities in infants. Several possible early biomarkers for hypoxic injury have been investigated but none of them have been completely utilized in clinical practice. Serum S100b is one such early biomarker. Object...

Full description

Saved in:
Bibliographic Details
Published in:Revista medicală Română 2024-03, Vol.71 (1), p.25-31
Main Authors: Reddy, O.Y. Pavan Kumar, Dash, Bibhudutta, Sarangi, Rachita, Ray, Subhashree
Format: Article
Language:English
Subjects:
hypoxic-ischemic encephalopathy
perinatal asphyxia
s 100b
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 31
container_issue 1
container_start_page 25
container_title Revista medicală Română
container_volume 71
creator Reddy, O.Y. Pavan Kumar
Dash, Bibhudutta
Sarangi, Rachita
Ray, Subhashree
description Background. Hypoxic ischemic encephalopathy (HIE) is a major cause of neurological disabilities in infants. Several possible early biomarkers for hypoxic injury have been investigated but none of them have been completely utilized in clinical practice. Serum S100b is one such early biomarker. Objective. The above study aims to assess the usefulness of the biomarker S100b in predicting the severity as well as the outcome of neonates having HIE. Materials and methods. A prospective cohort study was done on 80 term newborns admitted to the neonatal intensive care unit (NICU), Institute of medical sciences & SUM hospital, Bhubaneswar from August 2019 to February 2021. Out of the total 80 term newborns, 20 newborns without any evidence of perinatal hypoxia were categorized as the Controls, and the rest of 60 newborns with perinatal hypoxia were categorized as Cases. Cases were further divided into 3 subgroups based on Sarnat and Sarnat staging with 27 newborns in HIE I, 17 newborns in HIE II, and 16 newborns in HIE III. Serum S100b was measured in all the above children at 4 and 48 hours of life. Result. In our study, the mean serum S100b level at 4h & 48h of life was 1.15 & 1.05 respectively in controls and 3.24 & 2.36 (p
doi_str_mv 10.37897/RMJ.2024.1.4
format article
fullrecord <record><control><sourceid>doaj_cross</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ccd378b4be9d49f9b5cf885598f38ef3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ccd378b4be9d49f9b5cf885598f38ef3</doaj_id><sourcerecordid>oai_doaj_org_article_ccd378b4be9d49f9b5cf885598f38ef3</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1434-ba9f5694e1f663afe8836622994b5830c03a20326c6130a846fb3e459e8afc1d3</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhoMoWGqP3vMHtuZr08SbFj8qimAVvMUkO-mmtpslW6n9966tOJd3GJiHlwehc0rGfKL05OLl6WHMCBNjOhZHaMCI1IUk8v0YDShjpCjFRJ2iUdctST-SUM31AH3MIX-t8ZwS4i7xdUy-hnX0doXXNn9Cxilgl21scGXXdgG43xrYupSbDm_jpsb1rk3f0ePYHV4xNB7a2q5Sazf17gydBLvqYPSXQ_R2e_M6vS8en-9m06vHwlPBReGsDqXUAmiQktsASnEpGdNauFJx4gm3jHAmvaScWCVkcBxEqUHZ4GnFh2h24FbJLk2bY99_Z5KNZn9IeWFs3kS_AuN91StzwoGuhA7alT4oVZZaBa4g8J5VHFg-p67LEP55lJi9bdPbNr-2DTWC_wBFjnIe</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum S100b: Biochemical marker of brain damage in newborns with hypoxic ischemic encephalopathy</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Reddy, O.Y. Pavan Kumar ; Dash, Bibhudutta ; Sarangi, Rachita ; Ray, Subhashree</creator><creatorcontrib>Reddy, O.Y. Pavan Kumar ; Dash, Bibhudutta ; Sarangi, Rachita ; Ray, Subhashree ; Department of Pediatrics, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India ; Department of Biochemistry, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India</creatorcontrib><description><![CDATA[Background. Hypoxic ischemic encephalopathy (HIE) is a major cause of neurological disabilities in infants. Several possible early biomarkers for hypoxic injury have been investigated but none of them have been completely utilized in clinical practice. Serum S100b is one such early biomarker. Objective. The above study aims to assess the usefulness of the biomarker S100b in predicting the severity as well as the outcome of neonates having HIE. Materials and methods. A prospective cohort study was done on 80 term newborns admitted to the neonatal intensive care unit (NICU), Institute of medical sciences & SUM hospital, Bhubaneswar from August 2019 to February 2021. Out of the total 80 term newborns, 20 newborns without any evidence of perinatal hypoxia were categorized as the Controls, and the rest of 60 newborns with perinatal hypoxia were categorized as Cases. Cases were further divided into 3 subgroups based on Sarnat and Sarnat staging with 27 newborns in HIE I, 17 newborns in HIE II, and 16 newborns in HIE III. Serum S100b was measured in all the above children at 4 and 48 hours of life. Result. In our study, the mean serum S100b level at 4h & 48h of life was 1.15 & 1.05 respectively in controls and 3.24 & 2.36 (p<o.oo1) respectively in cases. The mean S100b level in subgroup HIE I, II, III were 2.06, 2.79 & 5.12 at 4h of life and 1.35, 1.86 & 4.08 at 48h of life, which is gradually increasing with the severity of asphyxia. On follow-up, it was found that babies with high S100b at 4h & 48 h of birth had more neurological sequelae. ROC curve depicted area under the curve was 0.80 showing high predictability of S100b for the neurological outcome. It was also seen that the cut-off value of 3.09 at 4 h has a sensitivity of 80% and specificity of 78.2%. Conclusion. Serum S100b is not only an early biomarker for HIE but also helps in prognostication, which is an essential part of the treatment of newborns and during the counseling of parents.]]></description><identifier>ISSN: 1220-5478</identifier><identifier>EISSN: 2069-606X</identifier><identifier>DOI: 10.37897/RMJ.2024.1.4</identifier><language>eng</language><publisher>Amaltea Medical Publishing House</publisher><subject>hypoxic-ischemic encephalopathy ; perinatal asphyxia ; s 100b</subject><ispartof>Revista medicală Română, 2024-03, Vol.71 (1), p.25-31</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-3852-9324 ; 0000-0002-1204-5746</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Reddy, O.Y. Pavan Kumar</creatorcontrib><creatorcontrib>Dash, Bibhudutta</creatorcontrib><creatorcontrib>Sarangi, Rachita</creatorcontrib><creatorcontrib>Ray, Subhashree</creatorcontrib><creatorcontrib>Department of Pediatrics, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India</creatorcontrib><creatorcontrib>Department of Biochemistry, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India</creatorcontrib><title>Serum S100b: Biochemical marker of brain damage in newborns with hypoxic ischemic encephalopathy</title><title>Revista medicală Română</title><description><![CDATA[Background. Hypoxic ischemic encephalopathy (HIE) is a major cause of neurological disabilities in infants. Several possible early biomarkers for hypoxic injury have been investigated but none of them have been completely utilized in clinical practice. Serum S100b is one such early biomarker. Objective. The above study aims to assess the usefulness of the biomarker S100b in predicting the severity as well as the outcome of neonates having HIE. Materials and methods. A prospective cohort study was done on 80 term newborns admitted to the neonatal intensive care unit (NICU), Institute of medical sciences & SUM hospital, Bhubaneswar from August 2019 to February 2021. Out of the total 80 term newborns, 20 newborns without any evidence of perinatal hypoxia were categorized as the Controls, and the rest of 60 newborns with perinatal hypoxia were categorized as Cases. Cases were further divided into 3 subgroups based on Sarnat and Sarnat staging with 27 newborns in HIE I, 17 newborns in HIE II, and 16 newborns in HIE III. Serum S100b was measured in all the above children at 4 and 48 hours of life. Result. In our study, the mean serum S100b level at 4h & 48h of life was 1.15 & 1.05 respectively in controls and 3.24 & 2.36 (p<o.oo1) respectively in cases. The mean S100b level in subgroup HIE I, II, III were 2.06, 2.79 & 5.12 at 4h of life and 1.35, 1.86 & 4.08 at 48h of life, which is gradually increasing with the severity of asphyxia. On follow-up, it was found that babies with high S100b at 4h & 48 h of birth had more neurological sequelae. ROC curve depicted area under the curve was 0.80 showing high predictability of S100b for the neurological outcome. It was also seen that the cut-off value of 3.09 at 4 h has a sensitivity of 80% and specificity of 78.2%. Conclusion. Serum S100b is not only an early biomarker for HIE but also helps in prognostication, which is an essential part of the treatment of newborns and during the counseling of parents.]]></description><subject>hypoxic-ischemic encephalopathy</subject><subject>perinatal asphyxia</subject><subject>s 100b</subject><issn>1220-5478</issn><issn>2069-606X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNo9kE1LAzEQhoMoWGqP3vMHtuZr08SbFj8qimAVvMUkO-mmtpslW6n9966tOJd3GJiHlwehc0rGfKL05OLl6WHMCBNjOhZHaMCI1IUk8v0YDShjpCjFRJ2iUdctST-SUM31AH3MIX-t8ZwS4i7xdUy-hnX0doXXNn9Cxilgl21scGXXdgG43xrYupSbDm_jpsb1rk3f0ePYHV4xNB7a2q5Sazf17gydBLvqYPSXQ_R2e_M6vS8en-9m06vHwlPBReGsDqXUAmiQktsASnEpGdNauFJx4gm3jHAmvaScWCVkcBxEqUHZ4GnFh2h24FbJLk2bY99_Z5KNZn9IeWFs3kS_AuN91StzwoGuhA7alT4oVZZaBa4g8J5VHFg-p67LEP55lJi9bdPbNr-2DTWC_wBFjnIe</recordid><startdate>20240331</startdate><enddate>20240331</enddate><creator>Reddy, O.Y. Pavan Kumar</creator><creator>Dash, Bibhudutta</creator><creator>Sarangi, Rachita</creator><creator>Ray, Subhashree</creator><general>Amaltea Medical Publishing House</general><scope>AAYXX</scope><scope>CITATION</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3852-9324</orcidid><orcidid>https://orcid.org/0000-0002-1204-5746</orcidid></search><sort><creationdate>20240331</creationdate><title>Serum S100b: Biochemical marker of brain damage in newborns with hypoxic ischemic encephalopathy</title><author>Reddy, O.Y. Pavan Kumar ; Dash, Bibhudutta ; Sarangi, Rachita ; Ray, Subhashree</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1434-ba9f5694e1f663afe8836622994b5830c03a20326c6130a846fb3e459e8afc1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>hypoxic-ischemic encephalopathy</topic><topic>perinatal asphyxia</topic><topic>s 100b</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reddy, O.Y. Pavan Kumar</creatorcontrib><creatorcontrib>Dash, Bibhudutta</creatorcontrib><creatorcontrib>Sarangi, Rachita</creatorcontrib><creatorcontrib>Ray, Subhashree</creatorcontrib><creatorcontrib>Department of Pediatrics, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India</creatorcontrib><creatorcontrib>Department of Biochemistry, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India</creatorcontrib><collection>CrossRef</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Revista medicală Română</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reddy, O.Y. Pavan Kumar</au><au>Dash, Bibhudutta</au><au>Sarangi, Rachita</au><au>Ray, Subhashree</au><aucorp>Department of Pediatrics, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India</aucorp><aucorp>Department of Biochemistry, IMS &amp; SUM Hospital, Bhubaneshwar, Odisha, India</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum S100b: Biochemical marker of brain damage in newborns with hypoxic ischemic encephalopathy</atitle><jtitle>Revista medicală Română</jtitle><date>2024-03-31</date><risdate>2024</risdate><volume>71</volume><issue>1</issue><spage>25</spage><epage>31</epage><pages>25-31</pages><issn>1220-5478</issn><eissn>2069-606X</eissn><abstract><![CDATA[Background. Hypoxic ischemic encephalopathy (HIE) is a major cause of neurological disabilities in infants. Several possible early biomarkers for hypoxic injury have been investigated but none of them have been completely utilized in clinical practice. Serum S100b is one such early biomarker. Objective. The above study aims to assess the usefulness of the biomarker S100b in predicting the severity as well as the outcome of neonates having HIE. Materials and methods. A prospective cohort study was done on 80 term newborns admitted to the neonatal intensive care unit (NICU), Institute of medical sciences & SUM hospital, Bhubaneswar from August 2019 to February 2021. Out of the total 80 term newborns, 20 newborns without any evidence of perinatal hypoxia were categorized as the Controls, and the rest of 60 newborns with perinatal hypoxia were categorized as Cases. Cases were further divided into 3 subgroups based on Sarnat and Sarnat staging with 27 newborns in HIE I, 17 newborns in HIE II, and 16 newborns in HIE III. Serum S100b was measured in all the above children at 4 and 48 hours of life. Result. In our study, the mean serum S100b level at 4h & 48h of life was 1.15 & 1.05 respectively in controls and 3.24 & 2.36 (p<o.oo1) respectively in cases. The mean S100b level in subgroup HIE I, II, III were 2.06, 2.79 & 5.12 at 4h of life and 1.35, 1.86 & 4.08 at 48h of life, which is gradually increasing with the severity of asphyxia. On follow-up, it was found that babies with high S100b at 4h & 48 h of birth had more neurological sequelae. ROC curve depicted area under the curve was 0.80 showing high predictability of S100b for the neurological outcome. It was also seen that the cut-off value of 3.09 at 4 h has a sensitivity of 80% and specificity of 78.2%. Conclusion. Serum S100b is not only an early biomarker for HIE but also helps in prognostication, which is an essential part of the treatment of newborns and during the counseling of parents.]]></abstract><pub>Amaltea Medical Publishing House</pub><doi>10.37897/RMJ.2024.1.4</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-3852-9324</orcidid><orcidid>https://orcid.org/0000-0002-1204-5746</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1220-5478
ispartof Revista medicală Română, 2024-03, Vol.71 (1), p.25-31
issn 1220-5478
2069-606X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ccd378b4be9d49f9b5cf885598f38ef3
source EZB-FREE-00999 freely available EZB journals
subjects hypoxic-ischemic encephalopathy
perinatal asphyxia
s 100b
title Serum S100b: Biochemical marker of brain damage in newborns with hypoxic ischemic encephalopathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T01%3A52%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20S100b:%20Biochemical%20marker%20of%20brain%20damage%20in%20newborns%20with%20hypoxic%20ischemic%20encephalopathy&rft.jtitle=Revista%20medical%C4%83%20Rom%C3%A2n%C4%83&rft.au=Reddy,%20O.Y.%20Pavan%20Kumar&rft.aucorp=Department%20of%20Pediatrics,%20IMS%20&%20SUM%20Hospital,%20Bhubaneshwar,%20Odisha,%20India&rft.date=2024-03-31&rft.volume=71&rft.issue=1&rft.spage=25&rft.epage=31&rft.pages=25-31&rft.issn=1220-5478&rft.eissn=2069-606X&rft_id=info:doi/10.37897/RMJ.2024.1.4&rft_dat=%3Cdoaj_cross%3Eoai_doaj_org_article_ccd378b4be9d49f9b5cf885598f38ef3%3C/doaj_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1434-ba9f5694e1f663afe8836622994b5830c03a20326c6130a846fb3e459e8afc1d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true